Skip to main content

Advertisement

SpringerLink
Log in

Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

An Erratum to this article was published on 18 November 2016

Abstract

Introduction

Poor sleep, depression, and anxiety are common in patients with inflammatory bowel diseases (IBD) and associated with increased risk of relapse and poor outcomes. The effectiveness of therapies in improving such psychosocial outcomes is unclear but is an important question to examine with increasing selectivity of therapeutic agents.

Methods

This prospective cohort enrolled patients with moderate-to-severe CD or UC starting biologic therapy with vedolizumab or anti-tumor necrosis factor α agents (anti-TNF). Sleep quality, depression, and anxiety were measured using validated short-form NIH PROMIS questionnaires assessing sleep and mood quality over the past 7 days. Disease activity was assessed using validated indices. Improvement in sleep and mood scores from baseline was assessed, and regression models were used to identify determinants of sleep quality.

Results

Our study included 160 patients with IBD (49 anti-TNF, 111 Vedolizumab) among whom half were women and the mean age was 40.2 years. In the combined cohort, we observed a statistically significant and meaningful decrease in mean scores from baseline (52.8) by week 6 (49.8, p = 0.002). Among vedolizumab users, sleep T-score improved from baseline (53.6) by week 6 (50.7) and persisted through week 54 (46.5, p = 0.009). Parallel reductions in depression and anxiety were also noted (p < 0.05 by week 6). We observed no difference in improvement in sleep, depression, and anxiety between vedolizumab and anti-TNF use at week 6.

Conclusions

Both vedolizumab and anti-TNF biologic therapies were associated with improvement in sleep and mood quality in IBD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–2078.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54 e42; quiz e30.

  3. Bernstein CN, Loftus EV Jr, Ng SC, et al. Hospitalisations and surgery in Crohn’s disease. Gut. 2012;61:622–629.

    Article  PubMed  Google Scholar 

  4. Graff LA, Vincent N, Walker JR, et al. A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1882–1889.

    Article  PubMed  Google Scholar 

  5. Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis. 2009;15:1105–1118.

    Article  PubMed  Google Scholar 

  6. Hommes D, Colombel JF, Emery P, et al. Changing Crohn’s disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012;6:S224–S234.

    Article  PubMed  Google Scholar 

  7. Hauser W, Janke KH, Klump B, et al. Anxiety and depression in patients with inflammatory bowel disease: comparisons with chronic liver disease patients and the general population. Inflamm Bowel Dis. 2011;17:621–632.

    Article  PubMed  Google Scholar 

  8. Walker JR, Ediger JP, Graff LA, et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol. 2008;103:1989–1997.

    Article  PubMed  Google Scholar 

  9. Kurina LM, Goldacre MJ, Yeates D, et al. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health. 2001;55:716–720.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ananthakrishnan AN. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2013;9:367–374.

    Google Scholar 

  11. Ananthakrishnan AN, Khalili H, Pan A, et al. Association between depressive symptoms and incidence of Crohn’s disease and ulcerative colitis: results from the Nurses’ Health Study. Clin Gastroenterol Hepatol. 2013;11:57–62.

    Article  PubMed  Google Scholar 

  12. Lerebours E, Gower-Rousseau C, Merle V, et al. Stressful life events as a risk factor for inflammatory bowel disease onset: a population-based case-control study. Am J Gastroenterol. 2007;102:122–131.

    Article  PubMed  Google Scholar 

  13. Tocchi A, Lepre L, Liotta G, et al. Familial and psychological risk factors of ulcerative colitis. Ital J Gastroenterol Hepatol. 1997;29:395–398.

    CAS  PubMed  Google Scholar 

  14. Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol. 2009;104:1298–313; quiz 1314.

  15. Bernstein CN, Singh S, Graff LA, et al. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol. 2010;105:1994–2002.

    Article  PubMed  Google Scholar 

  16. Ananthakrishnan AN, Gainer VS, Perez RG, et al. Psychiatric co-morbidity is associated with increased risk of surgery in Crohn’s disease. Aliment Pharmacol Ther. 2013;37:445–454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Gaines LS, Slaughter JC, Horst SN, et al. Association between affective-cognitive symptoms of depression and exacerbation of Crohn’s disease. Am J Gastroenterol. 2016;111:864–870.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Mikocka-Walus A, Pittet V, Rossel JB, et al. Symptoms of depression and anxiety are independently associated with clinical recurrence of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14:829–835 e1.

  19. Haack M, Sanchez E, Mullington JM. Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. Sleep. 2007;30:1145–1152.

    PubMed  PubMed Central  Google Scholar 

  20. Uthgenannt D, Schoolmann D, Pietrowsky R, et al. Effects of sleep on the production of cytokines in humans. Psychosom Med. 1995;57:97–104.

    Article  CAS  PubMed  Google Scholar 

  21. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab. 1997;82:1313–1316.

    Article  CAS  PubMed  Google Scholar 

  22. Wilson RG, Stevens BW, Guo AY, et al. High C-reactive protein is associated with poor sleep quality independent of nocturnal symptoms in patients with inflammatory bowel disease. Dig Dis Sci. 2015;60:2136–2143.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ali T, Madhoun MF, Orr WC, et al. Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis. 2013;19:2440–2443.

    Article  PubMed  Google Scholar 

  24. Ananthakrishnan AN, Long MD, Martin CF, et al. Sleep disturbance and risk of active disease in patients with Crohn’s disease and ulcerative colitis. Clin Gastroenterol Hepatol. 2013;11:965–971.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Keefer L, Stepanski EJ, Ranjbaran Z, et al. An initial report of sleep disturbance in inactive inflammatory bowel disease. J Clin Sleep Med. 2006;2:409–416.

    PubMed  Google Scholar 

  26. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Sleep duration affects risk for ulcerative colitis: a prospective cohort study. Clin Gastroenterol Hepatol. 2014;12:1879–1886.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ranjbaran Z, Keefer L, Farhadi A, et al. Impact of sleep disturbances in inflammatory bowel disease. J Gastroenterol Hepatol. 2007;22:1748–1753.

    Article  PubMed  Google Scholar 

  28. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–1605.

    Article  PubMed  Google Scholar 

  29. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380:1606–1619.

    Article  PubMed  Google Scholar 

  30. Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn’s disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007;26:987–1003.

    Article  CAS  PubMed  Google Scholar 

  31. Chande N, Patton PH, Tsoulis DJ, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;CD000067. doi:10.1002/14651858.CD000067.pub3.

  32. McDonald JW, Wang Y, Tsoulis DJ, et al. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2014;CD003459. doi:10.1002/14651858.CD003459.pub4.

  33. Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537–545.

    Article  CAS  PubMed  Google Scholar 

  34. D’Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn’s disease. Curr Gastroenterol Rep. 2006;8:506–512.

    Article  PubMed  Google Scholar 

  35. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.

    Article  CAS  PubMed  Google Scholar 

  36. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.

    Article  CAS  PubMed  Google Scholar 

  37. Weinberger JF, Raison CL, Rye DB, et al. Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation. Brain Behav Immun. 2015;47:193–200.

    Article  CAS  PubMed  Google Scholar 

  38. Zamarron C, Maceiras F, Mera A, et al. Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis. Ann Rheum Dis. 2004;63:88–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Ersozlu-Bozkirli ED, Keskek SO, Bozkirli E, et al. The effect of infliximab on depressive symptoms in patients with ankylosing spondylitis. Acta Reumatol Port. 2015;40:262–267.

    CAS  PubMed  Google Scholar 

  40. Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:1982–1992.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Ananthakrishnan AN, Cagan A, Cai T, et al. Common genetic variants influence circulating vitamin D levels in inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:2507–2514.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Pringle PL, Stewart KO, Peloquin JM, et al. Body mass index, genetic susceptibility, and risk of complications among individuals with Crohn’s disease. Inflamm Bowel Dis. 2015;21:2304–2310.

    PubMed  PubMed Central  Google Scholar 

  43. Ananthakrishnan AN, Huang H, Nguyen DD, et al. Differential effect of genetic burden on disease phenotypes in Crohn’s disease and ulcerative colitis: analysis of a North American cohort. Am J Gastroenterol. 2014;109:395–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;1:514.

    Article  CAS  PubMed  Google Scholar 

  45. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571–1578.

    CAS  PubMed  Google Scholar 

  47. Buysse DJ, Yu L, Moul DE, et al. Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments. Sleep. 2010;33:781–792.

    PubMed  PubMed Central  Google Scholar 

  48. Yu L, Buysse DJ, Germain A, et al. Development of short forms from the PROMIS sleep disturbance and sleep-related impairment item banks. Behav Sleep Med. 2011;10:6–24.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Kappelman MD, Long MD, Martin C, et al. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1315–1323 e2.

  50. Schalet BD, Pilkonis PA, Yu L, et al. Clinical validity of PROMIS depression, anxiety, and anger across diverse clinical samples. J Clin Epidemiol. 2016;73:119–127.

    Article  PubMed  Google Scholar 

  51. Irwin MR, Wang M, Campomayor CO, et al. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med. 2006;166:1756–1762.

    Article  CAS  PubMed  Google Scholar 

  52. Krueger JM, Obal FJ, Fang J, et al. The role of cytokines in physiological sleep regulation. Ann N Y Acad Sci. 2001;933:211–221.

    Article  CAS  PubMed  Google Scholar 

  53. Krueger JM, Rector DM, Churchill L. Sleep and cytokines. Sleep Med Clin. 2007;2:161–169.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Karadag O, Nakas D, Kalyoncu U, et al. Effect of anti-TNF treatment on sleep problems in ankylosing spondylitis. Rheumatol Int. 2012;32:1909–1913.

    Article  CAS  PubMed  Google Scholar 

  55. Taylor-Gjevre RM, Gjevre JA, Nair BV, et al. Improved sleep efficiency after anti-tumor necrosis factor alpha therapy in rheumatoid arthritis patients. Ther Adv Musculoskelet Dis. 2011;3:227–233.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Ghia JE, Blennerhassett P, Deng Y, et al. Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology. 2009;136:2280–2288 e1–4.

  57. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–186.

    Article  CAS  PubMed  Google Scholar 

  58. Horst S, Chao A, Rosen M, et al. Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease. Dig Dis Sci. 2015;60:465–470.

    Article  CAS  PubMed  Google Scholar 

  59. Guloksuz S, Wichers M, Kenis G, et al. Depressive symptoms in Crohn’s disease: relationship with immune activation and tryptophan availability. PLoS One. 2013;8:e60435.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Ali T, Orr WC. Sleep disturbances and inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1986–1995.

    Article  PubMed  Google Scholar 

  61. Targownik LE, Nugent Z, Singh H, et al. The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis. Am J Gastroenterol. 2014;109:1613–1620.

    Article  CAS  PubMed  Google Scholar 

  62. Sanford D, Thornley P, Teriaky A, et al. Opioid use is associated with decreased quality of life in patients with Crohn’s disease. Saudi J Gastroenterol. 2014;20:182–187.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author contributions

Stevens, Borren, Velonias, Conway, Cleland, Andrews, Khalili, Garber, Xavier, and Yajnik: study design, data collection, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. Ananthakrishnan: study design, data collection, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, and study supervision.

Funding

This work is supported by the National Institutes of Health (NIH) (P30 DK043351) to the Center for Study of Inflammatory Bowel Diseases. Ananthakrishnan is supported in part by a Grant from the National Institutes of Health (K23 DK097142).

Author information

Author notes

    Authors and Affiliations

    1. Division of Gastroenterology, Massachusetts General Hospital Crohn’s and Colitis Centre, 165 Cambridge Street, 9th Floor, Boston, MA, 02114, USA

      Betsy W. Stevens, Nynke Z. Borren, Gabriella Velonias, Grace Conway, Thom Cleland, Elizabeth Andrews, Hamed Khalili, John G. Garber, Ramnik J. Xavier, Vijay Yajnik & Ashwin N. Ananthakrishnan

    2. University of Groningen, Groningen, The Netherlands

      Nynke Z. Borren

    3. Harvard Medical School, Boston, MA, USA

      Hamed Khalili, John G. Garber, Ramnik J. Xavier, Vijay Yajnik & Ashwin N. Ananthakrishnan

    Authors
    1. Betsy W. Stevens
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Nynke Z. Borren
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Gabriella Velonias
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Grace Conway
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Thom Cleland
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Elizabeth Andrews
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Hamed Khalili
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. John G. Garber
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Ramnik J. Xavier
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Vijay Yajnik
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Ashwin N. Ananthakrishnan
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Ashwin N. Ananthakrishnan.

    Ethics declarations

    Conflict of interest

    Ananthakrishnan has served on scientific advisory boards for Abbvie, Takeda, and Merck.

    Additional information

    Betsy W. Stevens and Nynke Z. Borren equally contributed as first authors.

    An erratum to this article is available at http://dx.doi.org/10.1007/s10620-016-4380-2.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    10620_2016_4356_MOESM1_ESM.tif

    Change in depression and anxiety T-scores with use of anti-tumor necrosis factor α biologic therapy in inflammatory bowel diseases (TIFF 53 kb)

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Stevens, B.W., Borren, N.Z., Velonias, G. et al. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. Dig Dis Sci 62, 197–206 (2017). https://doi.org/10.1007/s10620-016-4356-2

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s10620-016-4356-2

    Keywords

    Search

    Navigation